Applying synthetic lethality for the selective targeting of cancer

New England Journal of Medicine

Volumn 371, Issue 18, 2014, Pages 1725-1735

  McLornan, Donal P ^a   List, Alan ^b   Mufti, Ghulam J ^a  

^a KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIRAPARIB; OLAPARIB; RUCAPARIB; TALAZOPARIB; VELIPARIB; ANTINEOPLASTIC AGENT; KRAS PROTEIN, HUMAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; ONCOPROTEIN; RAS PROTEIN;

CANCER CELL; CANCER CELL DESTRUCTION; CANCER CELL SYNTHETIC LETHALITY; CELL CYCLE CHECKPOINT; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG SPECIFICITY; DRUG TARGETING; ENZYME INHIBITION; GENE TARGETING; GENETIC ASSOCIATION; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; ONCOGENE K RAS; ONCOGENE MYC; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SINGLE STRANDED DNA BREAK; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; UBIQUITINATION; DRUG ANTAGONISM; DRUG DEVELOPMENT; GENETICS; LETHAL GENE; MUTATION; NEOPLASM;

ANTINEOPLASTIC AGENTS; DNA REPAIR; DRUG DISCOVERY; GENES, LETHAL; GENES, MYC; HUMANS; MUTATION; NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS; RAS PROTEINS;

EID: 84908406633     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra1407390     Document Type: Review

References (80)

1. Wright S, Dobzhansky T. Genetics of natural populations. XII. Experimental reproduction of some of the changes caused by natural selection in certain populations of Drosophila pseudoobscura. Genetics 1946;31: 125-56.
2. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434: 913-7.
3. Erratum, Nature 2007;447: 346.]
4. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434: 917-21.
5. Steckel M, Molina-Arcas M, Weigelt B, et al. Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies. Cell Res 2012;22: 1227-45.
6. Pourdehnad M, Truitt ML, Siddiqi IN, Ducker GS, Shokat KM, Ruggero D. Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers. Proc Natl Acad Sci U S A 2013;110: 11988-93.
7. Erratum, Proc Natl Acad Sci U S A 2013; 110: 1760
8. Chan N, Koritzinsky M, Zhao H, et al. Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Res 2008;68: 605-14.
9. Dörr JR, Yu Y, Milanovic M, et al. Synthetic lethal metabolic targeting of cellular senescence in cancer therapy. Nature 2013;501: 421-5.
10. Lee MJ, Ye AS, Gardino AK, et al. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 2012;149: 780-94.
11. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature 2009;461: 1071-8.
12. Lin YF, Shih HY, Shang Z, Matsunaga S, Chen BP. DNA-PKcs is required to maintain stability of Chk1 and Claspin for optimal replication stress response. Nucleic Acids Res 2014;42: 4463-73.
13. Khanna KK, Jackson SP. DNA doublestrand breaks: Signaling, repair and the cancer connection. Nat Genet 2001;27: 247-54.
14. Haber JE. Partners and pathways: Repairing a double-strand break. Trends Genet 2000;16: 259-64.
15. Deriano L, Roth DB. Modernizing the nonhomologous end-joining repertoire: Alternative and classical NHEJ share the stage. Annu Rev Genet 2013;47: 433-55.
16. San Filippo J, Sung P, Klein H. Mechanism of eukaryotic homologous recombination. Annu Rev Biochem 2008;77: 229-57.
17. van den Bosch M, Bree RT, Lowndes NF. The MRN complex: Coordinating and mediating the response to broken chromosomes. EMBO Rep 2003;4: 844-9.
18. Polo SE, Jackson SP. Dynamics of DNA damage response proteins at DNA breaks: A focus on protein modifications. Genes Dev 2011;25: 409-33.
19. Scully R, Chen J, Plug A, et al. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 1997;88: 265-75.
20. Fortini P, Pascucci B, Parlanti E, Sobol RW, Wilson SH, Dogliotti E. Different DNA polymerases are involved in the short-and long-patch base excision repair in mammalian cells. Biochemistry 1998;37: 3575-80.
21. Gillet LCJ, Schärer OD. Molecular mechanisms of mammalian global genome nucleotide excision repair. Chem Rev 2006;106: 253-76.
22. Kunkel TA, Erie DA. DNA mismatch repair. Annu Rev Biochem 2005;74: 681-710.
23. Martin SA, McCabe N, Mullarkey M, et al. DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH or MLH1. Cancer Cell 2010;17: 235-48.
24. Martin SA, McCarthy A, Barber LJ, et al. Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2. EMBO Mol Med 2009;1: 323-37.
25. Schreiber V, Dantzer F, Ame JC, de Murcia G. Poly(ADP-ribose): Novel functions for an old molecule. Nat Rev Mol Cell Biol 2006;7: 517-28.
26. Masson M, Niedergang C, Schreiber V, Muller S, Menissier-de Murcia J, de Murcia G. XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol Cell Biol 1998;18: 3563-71.
27. Timinszky G, Till S, Hassa PO, et al. A macrodomain-containing histone rearranges chromatin upon sensing PARP1 activation. Nat Struct Mol Biol 2009; 16: 923-9.
28. Shibata A, Kamada N, Masumura K, et al. Parp-1 deficiency causes an increase of deletion mutations and insertions/rearrangements in vivo after treatment with an alkylating agent. Oncogene 2005;24: 1328-37.
29. Nosho K, Yamamoto H, Mikami M, et al. Overexpression of poly(ADP-ribose) polymerase-1 (PARP-1) in the early stage of colorectal carcinogenesis. Eur J Cancer 2006;42: 2374-81.
30. Wu LC, Wang ZW, Tsan JT, et al. Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nat Genet 1996;14: 430-40.
31. Moynahan ME, Chiu JW, Koller BH, Jasin M. Brca1 controls homology-directed DNA repair. Mol Cell 1999;4: 511-8.
32. Gowen LC, Avrutskaya AV, Latour AM, Koller BH, Leadon SA. BRCA1 required for transcription-coupled repair of oxidative DNA damage. Science 1998;281: 1009-12.
33. Retraction, Science 2003;300: 1657.]
34. Antoniou A, Pharoah PDP, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet 2003;72: 1117-30.
35. Erratum, Am J Hum Genet 2003;73: 709.]
36. Begg CB, Haile RW, Borg A, et al. Variation of breast cancer risk among BRCA1/2 carriers. JAMA 2008;299: 194-201.
37. Yarden RI, Papa MZ. BRCA1 at the crossroad of multiple cellular pathways: Approaches for therapeutic interventions. Mol Cancer Ther 2006;5: 1396-404.
38. Ashworth A. A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 2008;26: 3785-90.
39. McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006;66: 8109-15.
40. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361: 123-34.
41. Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial. Lancet 2010;376: 235-44.
42. Molife LR, Roxburgh P, RH Wilson, et al. A phase I study of oral rucaparib in combination with carboplatin. J Clin Oncol 2013;31: Suppl: 2586. abstract.
43. Kristeleit RS, Shapiro G, LoRusso P et al. A phase I dose-escalation and PK study of continuous oral rucaparib in patients with advanced solid tumors. J Clin Oncol 2013;31: Suppl: 2585. abstract.
44. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012;366: 1382-92.
45. Bang YJ, Im AS, Lee KW, et al. Olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer: A randomized, double-blind phase II study. J Clin Oncol 2013;31: Suppl: 4013. abstract.
46. Bell-McGuinn K, Gray HJ, Fleming GF, et al. Phase I study of ABT-888 in combination with carboplatin and gemcitabine in subjects with advanced solid tumors. J Clin Oncol 2013;31: Suppl: 2584. abstract.
47. Michie CO, Sandhu SK, Schelman WR. Final results of the phase I trial of niraparib (MK4827), a poly(ADP)ribose polymerase (PARP) inhibitor incorporating proof of concept biomarker studies and expansion cohorts involving BRCA1/2 mutation carriers, sporadic ovarian, and castration resistant prostate cancer (CRPC). J Clin Oncol 2013;31: Suppl: 2513. abstract.
48. De Bono JS, Mina LA, Gonzalez M, et al. First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors. J Clin Oncol 2013;31: Suppl: 2580. abstract.
49. Wahlberg E, Karlberg T, Kouznetsova E, et al. Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors. Nat Biotechnol 2012;30: 283-8.
50. Weaver AN, Yang ES. Beyond DNA repair: Additional functions of PARP-1 in cancer. Front Oncol 2013;3: 290.
51. Murai J, Huang SY, Das BB, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 2012;72: 5588-99.
52. Murai J, Huang SY, Renaud A, et al. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther 2014;13: 433-43.
53. Chiarugi A. A snapshot of chemoresistance to PARP inhibitors. Trends Pharmacol Sci 2012;33: 42-8.
54. Jacquemont C, Taniguchi T. Proteasome function is required for DNA damage response and Fanconi anemia pathway activation. Cancer Res 2007;67: 7395-405.
55. Neri P, Ren L, Gratton K, et al. Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors. Blood 2011;118: 6368-79.
56. Vollebergh MA, Lips EH, Nederlof PM, et al. An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Ann Oncol 2011;22: 1561-70.
57. Lips EH, Laddach N, Savola SP, et al. Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness. Breast Cancer Res 2011;13: R107.
58. Konstantinopoulos PA, Spentzos D, Karlan BY, et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol 2010;28: 3555-61.
59. Erratum, J Clin Oncol 2010;28: 4868.]
60. Ebert BL, Pretz J, Bosco J, et al. Identification of RPS14 as a 5q-syndrome gene by RNA interference screen. Nature 2008;451: 335-9.
61. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005;352: 549-57.
62. Wei S, Chen X, Rocha K, et al. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci U S A 2009;106: 12974-9.
63. Erratum, Proc Natl Acad Sci U S A 2013;110: 14504.]
64. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408: 307-10.
65. Lehmann S, Bykov VJ, Ali D, et al. Targeting p53 in vivo: A first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol 2012; 30: 3633-9.
66. Morandell S, Reinhardt HC, Cannell IG, et al. A reversible gene-targeting strategy identifies synthetic lethal interactions between MK2 and p53 in the DNA damage response in vivo. Cell Rep 2013;5: 868-77.
67. Jiang H, Reinhardt HC, Bartkova J, et al. The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev 2009;23: 1895-909.
68. Baldwin A, Grueneberg DA, Hellner K, et al. Kinase requirements in human cells: V. Synthetic lethal interactions between p53 and the protein kinases SGK2 and PAK3. Proc Natl Acad Sci U S A 2010;107: 12463-8.
69. Wang X, Simon R. Identification of potential synthetic lethal genes to p53 using a computational biology approach. BMC Med Genomics 2013;6: 30.
70. Schöffski P, Awada A, Dumez H, et al. A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. Eur J Cancer 2012;48: 179-86.
71. Mahadevan D, Stejskal A, Cooke LS, et al. Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma. Clin Cancer Res 2012;18: 2210-9.
72. Roberts PJ, Stinchcombe TE. KRAS mutation: Should we test for it, and does it matter? J Clin Oncol 2013;31: 1112-21.
73. Luo J, Emanuele MJ, Li D, et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009;137: 835-48.
74. Barbie DA, Tamayo P, Boehm JS, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009;462: 108-12.
75. Scholl C, Fröhling S, Dunn IF, et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 2009;137: 821-34.
76. Luo T, Masson K, Jaffe JD, et al. STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability. Proc Natl Acad Sci U S A 2012; 109: 2860-5.
77. Kumar MS, Hancock DC, Molina-Arcas M, et al. The GATA2 transcriptional network is requisite for RAS oncogenedriven non-small cell lung cancer. Cell 2012;149: 642-55.
78. Erler JT, Linding R. Network medicine strikes a blow against breast cancer. Cell 2012;149: 731-3.
79. Bristow RG, Hill RP. Hypoxia and metabolism: Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 2008;8: 180-92.
80. Chan N, Pires IM, Bencokova Z, et al. Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment. Cancer Res 2010;70: 8045-54.